XNAS
OPTH
Market cap22mUSD
, Last price
USD
Name
Optimi Health Corp
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
6.91%
Rev. gr., 5y
%
Revenues
427k
+9.50%
Net income
0
P
CFO
-3m
L-38.62%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Princeton, Canada, Optimi Health Corp., established in 2020, is a Canadian entity focused on manufacturing pharmaceutical and nutraceutical products. The company produces and supplies controlled substances, including finalized MDMA and psilocybin drug products, directly to authorized clinics, pharmacies, research trials, and collaborative partners. Their diverse product portfolio extends to MDMA, natural psilocybin, psilocin, other psychedelic compounds, and functional mushrooms, all derived from botanical sources and aimed at the health and wellness market. Optimi Health's operations span cultivation, processing, and distribution of raw mushroom biomass, alongside the creation of mushroom extracts, pharmaceutical drug products, and dietary supplements. These items are available for purchase through the Amazon marketplace, via distributors and brokers, and directly online.
Key people
Jacob Safarik
Chief Financial Officer, Director · since 2022
Bryan Safarik
Chief Operating Officer, Director · since 2020
Dane Stevens
Chief Executive Officer, Chief Marketing Officer and Director · since 2024
Jason Mosberian
Director · since 2025
James Wilson
Non-Executive Independent Chairman of the Board · since 2020
Headquarters & legal address
40440 THUNDERBIRD RIDGE B1831
GARIBALDI HIGHLANDS, BC V0N 1T0
CA
GARIBALDI HIGHLANDS, BC V0N 1T0
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||